Navigation Links
IBT Laboratories Expands its Menu of Tests for Immune Deficiency

LENEXA, Kan., Dec. 2 /PRNewswire/ -- IBT Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing in immunology and allergy assays, announced that it has launched two tests to evaluate the response of patients whose immune systems may be compromised due to a primary immunodeficiency disorder, chemotherapy drugs, or because they are taking immuno-suppressing drugs to prevent rejection of a transplant. The company launched the two new assays, the T Cell FxTM test and the Mannan Binding Lectin (MBL) Pathway Function Test, at the November 2008 meeting of the American College of Allergy Asthma and Immunology in Seattle.

According to IBT Founder and Chief Executive Officer, John F. Halsey, Ph.D., these two tests provide physicians with much greater insight into a patient's immunology profile than was possible before. "We rely on our body's immune system to defend us from infectious disease. When a patient has an unusual number of infections, physicians need a complete assessment of the capabilities of the patient's immune system to respond to challenge by microorganisms. Both innate and adaptive immunity need to be evaluated. Previously, these kinds of tests were only used by the research community, and were not available in the clinical-diagnostics laboratory."

Regarding company strategy, Dr. Halsey commented, "Our assay-development strategy at IBT is to work closely with leading allergists and immunologists to translate the latest research findings into new diagnostic tests that will help them better understand and manage their patients' health status, and ultimately improve health outcomes."

The MBL pathway is one of the most important components of the innate immune system. IBT has developed a unique and quantitative serum test (MBL Pathway Function Test) to evaluate the effectiveness of this pathway. This test will be particularly useful to assess children with persistent, recurrent infections to determine whether their innate immune system is compromised. It will also help physicians to better manage transplant and oncology patients by identifying when prophylactic measures are appropriate.

T cells are a critical part of the patient's adaptiveimmune system and IBT's new T Cell FxTM test provides a complete evaluation of the ability of a patient's T cells to protect from viruses, yeast, and bacteria. The test, which looks at peripheral blood mononuclear cells from whole blood, will help physicians identify primary immunodeficiency in children with recurrent infections. For transplant populations, physicians can use the test to help monitor and manage the level of immuno-suppressing drugs.

These new test offerings add to IBT's extensive menu of tests that are available to assist physicians in the evaluation of patients with suspected immune deficiency. The company has recently expanded its research capacity and will be offering other new tests in the future to help doctors treat patients with allergies and immune deficiencies.

About IBT Laboratories

A clinical diagnostic and research laboratory specializing in immunology and allergy testing, IBT tests patient samples for physicians, hospitals, and commercial reference labs nationwide. IBT also provides biomarker and immunogenicity testing services to pharmaceutical and biotechnology companies and life-science researchers. Founded in 1983, IBT is privately held and centrally located in Lenexa, Kansas, a suburb of Kansas City.

    Media contact
    Caroline Grossman

SOURCE IBT Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
6. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
7. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  In the pharmaceutical ... in an effort to quickly uncover new insights, tactics ... --> --> However, organizations ... market research project and ensure that all rules and ... industry standards. Another major barrier to efficiently launching market ...
(Date:11/24/2015)... NEWPORT NEWS, Va. , Nov. 24, 2015 /PRNewswire/ ... that they have signed an agreement for DILON to ... select geographies across the globe. The signing of this distribution ... GE,s Discovery NM750b Molecular Breast Imaging system and is ... ways to provide better healthcare solutions for clinicians and ...
(Date:11/24/2015)... 24, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Executive Officer Doug Godshall is scheduled to ... Healthcare Conference on December 1, 2015 at 3:00 p.m. ... New York . ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to ... it is critical that the first impression be positive and reflects business values. If ... to buy anything or want to return. They will also share their thoughts about ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... In response ... growing epidemic as deaths from prescription opioids in the United States grew 400 percent ... In 2013 alone, opioids were involved in 37 percent of all fatal drug overdoses. ...
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association of ... local poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, the ... that inspires people to collaborate in improving their local communities and help give ...
(Date:11/24/2015)... ... ... With Thanksgiving right around the corner, holiday travel season is about to ... and vehicle. , According to the National Highway Traffic Safety Administration, 301 people were ... following safety tips from the NHTSA: , Inspect ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington ... an Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals living with ... of health care services available to its members to help them make informed ...
Breaking Medicine News(10 mins):